X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (203) 203
index medicus (194) 194
hematology (121) 121
male (117) 117
female (113) 113
middle aged (108) 108
aged (101) 101
multiple myeloma (96) 96
oncology (89) 89
adult (83) 83
bortezomib (66) 66
multiple myeloma - drug therapy (56) 56
life sciences (55) 55
aged, 80 and over (54) 54
survival (50) 50
prognosis (48) 48
multiple myeloma - pathology (41) 41
cancer (39) 39
multiple-myeloma (39) 39
treatment outcome (38) 38
therapy (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
abridged index medicus (34) 34
multiple myeloma - mortality (33) 33
dexamethasone (32) 32
waldenstrom macroglobulinemia - drug therapy (29) 29
animals (28) 28
waldenstrom macroglobulinemia - pathology (28) 28
lenalidomide (27) 27
patients (26) 26
thalidomide - analogs & derivatives (25) 25
diagnosis (24) 24
expression (24) 24
multiple myeloma - genetics (24) 24
retrospective studies (24) 24
survival analysis (24) 24
thalidomide (24) 24
risk factors (23) 23
care and treatment (22) 22
chemotherapy (22) 22
dexamethasone - administration & dosage (22) 22
article (21) 21
hematology, oncology and palliative medicine (21) 21
analysis (20) 20
mice (20) 20
stem-cell transplantation (20) 20
transplantation (20) 20
antineoplastic agents - therapeutic use (19) 19
disease progression (19) 19
follow-up studies (18) 18
international workshop (18) 18
monoclonal gammopathy (18) 18
recurrence (18) 18
research (18) 18
rituximab (18) 18
survival rate (18) 18
waldenstrom macroglobulinemia - genetics (18) 18
boronic acids - administration & dosage (17) 17
cell line, tumor (17) 17
multiple myeloma - diagnosis (17) 17
pyrazines - administration & dosage (17) 17
bone marrow (16) 16
chronic lymphocytic-leukemia (16) 16
disease-free survival (16) 16
kaplan-meier estimate (16) 16
myeloma (16) 16
prospective studies (16) 16
thalidomide - administration & dosage (16) 16
apoptosis (15) 15
recommendations (15) 15
risk (15) 15
cells (14) 14
leukemia (14) 14
lymphoma (14) 14
waldenstrom macroglobulinemia (14) 14
chemical sciences (13) 13
immunology (13) 13
medical research (13) 13
mutation (13) 13
proteins (13) 13
stem cells (13) 13
waldenstrom macroglobulinemia - metabolism (13) 13
[sdv.can]life sciences [q-bio]/cancer (12) 12
[sdv]life sciences [q-bio] (12) 12
carfilzomib (12) 12
flow cytometry (12) 12
france (12) 12
health aspects (12) 12
hemic and lymphatic diseases (12) 12
multiple myeloma - metabolism (12) 12
multiple myeloma - therapy (12) 12
relapse (12) 12
remission induction (12) 12
studies (12) 12
clinical trials (11) 11
combination (11) 11
disease (11) 11
medicine, general & internal (11) 11
micrornas - genetics (11) 11
stem cell transplantation (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Journal Article
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 4/2013, Volume 39, Issue 4, pp. 629 - 635
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, p. e0158719
Journal Article